Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Hard to fault but overvalued

Wesfarmers
3:27pm
August 28, 2025
WES’s FY25 result was largely in line with expectations. Earnings for most divisions were in line with our forecasts. Health was a standout with a stronger-than-expected jump in earnings. The announcement of a $1.50ps capital return (comprising a fully-franked special dividend of $0.40ps and capital component of $1.10ps) was another highlight. Management said the retail divisions traded well in the first 8 weeks of FY26. Encouragingly, they have seen a modest improvement in consumer demand on the back of a moderation in inflation and the recent interest rate cuts. We make minimal changes to earnings forecasts but lift our target price to $83.20 (from $75.80). This reflects another solid result, demonstrating strong execution by management and early signs of improvement in consumer sentiment, which should support a more positive outlook for trading conditions. With a forecast 12-month TSR of -6%, we maintain our TRIM rating. While we continue to view WES as a core long-term portfolio holding with a diversified group of well-known retail and industrial brands, a healthy balance sheet, and an experienced leadership team with a strong track record of growth, trading on 36.9x FY26F PE we see the stock as overvalued in the short term.

Healthy earnings, but guidance reset weighs

South32
3:27pm
August 28, 2025
FY25 result steady, but FY26 guidance reset at Mozal (C&M risk) and Cannington (lower throughput, higher costs) clouds near-term earnings. Hermosa build year pushes group capex to US$1.4bn in FY26, keeping FCF tight despite trimmed sustaining spend. Sierra Gorda copper volumes up 20%, but limited near-term catalysts and consensus downgrades pressure weigh on sentiment. Dividend of US 2.6cps; US$144m remains in buyback program. Maintain BUY with reduced target price of A$3.55 (was A$4.10).

More Supply Agreements needed

Micro-X
3:27pm
August 28, 2025
MX1 posted its FY25 result, which was behind our forecasts. Lower product sales was the area we underestimated. However, the recent signing of a Supply Agreement with a major healthcare provider should see sales of the Rover Plus increase in FY26 and FY27. We expect similar agreements are likely to follow. The focus on medical imaging appears to be paying off. We have made no changes to our forecasts and our target price remains unchanged at A$0.17. We maintain our SPECULATIVE BUY recommendation.

Brighter future ahead

Beacon Lighting
3:27pm
August 28, 2025
BLX reported NPAT decline of 0.7% on an underlying basis, which was ~7% lower than expected driven by lower LFL sales and higher operating costs. Encouragingly, sales momentum improved through the year and accelerated in the 4Q, and has been maintained into FY26. Trade sales continues to grow, with top line sales up >20%. Trade now represents 40% of relevant sales and the company remains on track for 50/50 split trade and retail by FY28. We have lowered our NPAT forecasts by 9%/7% respectively in FY26/27, pushing out the strong earnings recovery and operating leverage into FY27. We expect significant leverage in this business when consumer sentiment and housing cycle turns. We have upgraded to an ACCUMULATE, with a $3.80 TP (was $3.55).

Stabilising operations appear priced in

Mineral Resources
3:27pm
August 28, 2025
MIN delivered a solid FY25 result with EBITDA ahead of forecasts and underlying NPAT well ahead of forecasts on lower D&A and net interest. FY26 guidance was in line, although MorgansF/consensus were at the top-end of guidance. MIN confirmed Onslow has been running at a 35mtpa run rate for the last 4 weeks, and the haul road repair will complete in mid-September. We move to a TRIM rating with a A$34ps target price (previously A$31ps) reflecting our view that MIN’s stabilising operations are already priced in following its strong share price run.

Putting the trade back in the shade

Clinuvel Pharmaceuticals
3:27pm
August 28, 2025
FY25 result itself was marginally below expectations with higher-than-expected expenses delivered a miss to profit lines and a continued failure to change the narrative around capital management and disclosures which continues to keep a lid on the upside. Seasonal 2H strength carried the year along with margins still flattered by low materials costs which we expect will normalise in FY26. Cash balance remains an eyesore, now up to A$224m (~35% of market cap), and buy-back capacity effectively untouched and no uplift in dividend. We called CUV out as a potential beat candidate in our pre-reporting season report given the seasonally strong trading period, but happy to close out following a strong SP appreciation in the leadup. Our target price reduces to A$14 (from A$15) and we downgrade to a HOLD recommendation.

Backlog support underpins favorable outlook

Worley
3:27pm
August 28, 2025
WOR delivered a solid FY25 result, which came broadly in line with MorgF and consensus, with Underlying EBITA of $823m (+10% YoY), driven by Aggregate revenue growth 4%, Underlying EBITA margin (ex-procurement) improved 130bps. WOR’s outlook for FY26 remains positive with the group flagging that they are not seeing any material project cancellations, across end markets, providing confidence in moderate revenue growth & stable EBITA margins in FY26. We trim our Underlying EBITA forecast by -2%, in FY26/27F, to align more closely with the Groups outlook. This sees us retain our BUY rating and price target of $16.80/sh).

Shaping up for sales growth in FY26

ImpediMed
3:27pm
August 28, 2025
IPD posted its FY25 result reporting a net loss higher than our forecast. Importantly, the operating cash outflow was better than our expectations. Our focus is the growth of the installed base in the US which now seems to be gaining momentum with 4Q25 delivering a record 44 SOZO units. We expect subsequent quarters to continue to build on this. We have made modest downgrades to our short-term forecasts, which sees our valuation move to A$0.14 (from A$0.15). We maintain a SPECULATIVE BUY recommendation on IPD.

Prescription pressures

Ebos Group
3:27pm
August 28, 2025
EBO’s FY26 results were marginally below expectations, however the key disappointment lies in guidance which signaled a more cautious outlook, reflecting competitive pressures in pharmacy, softer hospital demand, and ongoing consumer weakness in discretionary categories. All issues potentially impacting negative sentiment into FY26 but we remind investors of EBO’s long history of strong EPS growth and consistent return on capital along with a growing dividend stream. Our target price moderates to A$34.82 but we retain an Accumulate rating.

Rare rewards

Neuren Pharmaceuticals
3:27pm
August 28, 2025
NEU delivered a strong first half, underpinned by continued growth in royalties resulting in a solid uplift in profitability. Operationally, momentum remains strong with record DAYBUE patient uptake in the US and progress toward global expansion and late-stage clinical programs. Key near-term drivers include continued DAYBUE uptake with quarterly updates from Acadia (ongoing), EU marketing authorisation decision expected in 1Q26, initiation of the Japan clinical trial in 3Q25, progress on the Ph3 PMS trial (site activations and enrollment updates through 2025), and FDA interactions for Pitt Hopkins and HIE programs later in 2025. Consensus target prices remain materially higher than current levels, sitting at A$23.86 per share, all with BUY recommendations.

News & insights

A detailed comparison of US productivity and global growth forecasts, highlighting key differences with Australia.

Why The US Has Higher Productivity

Good morning. Today I want to talk about the U.S. economy in comparison, to other economies and, why it's performing, the way it is. The documents I will refer to are first the IMF, outlook, which is,  come out in the last two weeks.  That gives us some international comparisons.

For the US economy I use, the monthly outlook from Standard and Poor's, which is, the number one rated by the Congressional Budget Office, well ahead of other economic forecasters. For the US economy, both the IMF and, Standard Poor's agree that growth this year should be 2%. Our own model of the US economy, based on the Chicago Fed National Activity Indicator, is also forcasting US growth of 2%.

Still, that's 2% is less whatever the negative effect is from, from the US shutdown. When the shutdown continues for a month, that growth rate falls from 2% down to about 1.8 % 1.7%. So it's a moderate slowdown. Still growth in the U.S. economy accelerates next year to about 2.2%. I'll talk later on where that growth is coming from.

When we look at growth in other areas we see that: Euro area is miserable. Great Britain is growing faster than the Euro area now. This year the UK should grow by 1.3% but, the Euro area should grow by about 1.2% this year. Euro area growth drifts off to an even more miserable 1.1% next year. But fortunately, that generates a lot of savings to invest in other countries like us. Those savings then go in to the US equities and bond markets and, the Australian stock market and places like that.

China is slowing down to 4.8% this year and 4.2% next year according to the, IMF. Still, heroically India, marches on to 6.6% growth this year and 6.2% next year. For emerging markets, which include the Indo Pacific generally ,Growth is proceeding  at about 5.2% this year and 4.7%, next year.

The U.S is still, pretty good in comparison. This year, it's, growing at 2% or, depending on  the results of the shutdown. Next US Growth accelerates, to 2.2%, and growth is then about the same the year after.

There's been a lot of debate this year about the effect of tariffs on the US inflation.  In spite of higher tariffs , US inflation is stubbornly , stubbornly low. Headline inflation, which includes food and energy this year should be only 2.8%. Hardly something to scare markets. And that continues a 2.9% next year and 2.5% the year after. Amazingly,US  core inflation is a bit higher than that 3% this year and 3.3% next year. It's just that food and energy prices are falling in the US. Why can't that happen here?

Lets look at one of the reasons that you get really quite steady growth and relatively low inflation in the US The comparison I want to make here is between US output per hour and Australian output per hour. In the beginning of this year, we had a shocking slowdown in productivity growth because our government decided that was better to hire more, people from the public service than generate employment in the private sector. It is well known that, productivity in the market economy grows much faster than in the, than in the public sector. So,  for the first quarter, productivity in Australia grew, or  output per hour worked per annum ,grew by 0.3%  . The RBA has told us that, they expect output per hour that will rise to about 0.7%per annum , the same as the UK. And we'll be able to maintain productivity growth rate of 0.7%, going forward.

Let's compare that to what's happening in the US economy. This year It looks like the US will be producing labour productivity much higher than the Australia.  US Output per hour should grow by 1.6% this year . Next year US Output per hour may grow  even more by, 2.1%. Following that US labour productivity the year should grow between 1.6 and 1.7%,. This is  full 1% faster than, the Australian economy is expected to grow in terms of productivity. Remember, it's growth and productivity which generates increase in living standards.

There's two reasons, that we can provide for why the U.S., productivity is growing so much faster than ours. One is a flexible labour market. It's an extremely flexible labour market in the US. The current Australian government has made our labour market less flexible, less than it previously was. A second reason is deregulation . The program of deregulation by the US administration is making it easier for business , to do business.

That, of course, in turn generates higher levels of business investment. That higher level of business investments creates more growth. So, it's a series of policies which are different in each country . The result will be that, living standards in, in the U.S are going to start going to be growing significantly faster than they are in Australia.

And that's the end of the good news for the day.

Read more
Australia's trimmed mean inflation hit 3%, driven by surging electricity prices and the end of federal subsidies, signalling the end of the rate-cut cycle.

Last time I spoke to you about Australian inflation and its effect on what the RBA might do in its November meeting, I said that expectations for inflation for the year to September, which would be published in October, were between 2.5% and 2.7%. I also said that if inflation came in at the lower estimate of 2.5%, then we could see a rate cut in November.

Well, the numbers are out, and unfortunately, not only are we not getting a rate cut in November, it’s unlikely we’ll see another rate cut any time soon. In fact, it’s fair to say we may be at the very end of the rate-cutting cycle in Australia. The reason is that the core measure, the trimmed mean, which is the RBA’s preferred measure of underlying inflation, came in not at 2.5%, not at 2.6%, and not even at 2.7%, but at a shockingly high 3%.

This result was driven by a 1.3% increase in prices in the previous quarter, which annualises to about 5%, a surprise that wasn’t anticipated. Looking deeper into the quarterly CPI, we saw housing prices rising at 4.7%, health costs up 4.2%, and education costs increasing by 5.3%.

The ABS has indicated that the major source of inflation was a jump in goods inflation, which rose 3%, up 1.1% from the previous quarter, or 4.4% annualised. The standout contributor was electricity, which saw a massive year-on-year increase of 23.6%. Other household fuels actually fell by 1.6%, and annual services inflation was 3.5%.

The ABS attributed this unexpected rise in inflation primarily to electricity prices. But it’s not just electricity prices themselves, it’s the end of Federal Government funding to the states that had been keeping those prices low.

The ABS reported that electricity prices rose 23.6% over the past 12 months, largely because State Government rebates, funded by the Commonwealth under the Energy Bill Relief Fund, have now been used up. These rebates included Queensland’s $1,000 rebate, Western Australia’s $400 rebate, and Tasmania’s $250 rebate. With these rebates exhausted, electricity prices have surged.

The A

BS data shows electricity prices excluding government rebates, and highlights the impact of the federal funding. Electricity prices really took off in 2023, rising by almost 20%, which posed a political risk for the Federal Government. In response, the Government provided funding to State Governments to suppress those prices. There were schemes in both 2023 and 2024, and ahead of the last election, the subsidised price paid by consumers dropped to around 80% of the original cost, well below the actual cost of generation.

However, since December 2024, those subsidies have been reduced. Over the past year, prices have climbed again, though they remain below the unsubsidised cost, which is now around 122% of the original price, or about a quarter higher than where things stood in 2023.

The result of all this is 3% core inflation. If inflation had come in at 2.5%, rates could have fallen from 3.6% to 3.35%. But with 3% core inflation, rates should need to rise by 25 basis points. That said, we’re likely at the end of the rate-cut cycle.

Is the RBA likely to raise rates? They might consider it, but this is cost-push inflation, not demand-driven inflation, so increasing rates wouldn’t help. It would only worsen the situation. This very high inflation figure, driven by the end of federal electricity subsidies, signals the end of the current series of Australian rate cuts.

Read more
Receiving a large inheritance can be life-changing, but it also comes with important financial decisions.

Key Takeaways

  • Press pause. Park funds safely while you confirm what you received, obligations, and any tax implications.
  • Build a plan that fits your goals and timeframes. Prioritise cash buffers, debt decisions, investing, super, and estate wishes.
  • Get advice early. A financial adviser and tax accountant can help you avoid costly mistakes and set up a long-term strategy.
  • Use professional inheritance financial advice to align tax, super, investing, and estate planning decisions.

Receiving a large inheritance can be life-changing. It can also feel overwhelming. The right first steps help you protect capital, make clear decisions, and turn a windfall into lasting financial security. This guide walks you through a practical process Morgans advisers use with clients every day, with a focus on inheritance financial advice tailored to Australian rules.

Step 1: Pause and assess your situation

Before making big choices, slow down.

  • List the assets you have inherited: cash, property, superannuation, shares, term deposits, insurance proceeds, or a business interest.
  • Confirm control and timing. Has probate been granted? Are there executor timelines or sale constraints?
  • Check any liabilities. Some assets may come with debts, fees, rates, or ongoing costs.
  • Gather documents. Will, probate, estate distribution statement, title records, super death-benefit statements, cost-base records for property and shares.

Short term, consider holding funds in high-interest savings or term deposits while you complete the groundwork. ASIC’s Moneysmart has clear tips on handling large amounts of money.

Step 2: Understand the emotional impact

An inheritance often follows the loss of a loved one. It is normal to feel pressure to act quickly. Give yourself time.

  • Avoid large purchases until you have a plan.
  • Set simple rules. For example, no irreversible decisions for 30 to 90 days.
  • Write down your goals and values. What will this money do for you, your family, or future generations?
  • If you feel rushed by offers or schemes, step back and check for red flags. Scamwatch has practical guidance.

Step 3: Map your goals and timeframes

Your strategy should mirror when you will need the money.

  • 0 to 2 years (short term): capital protection and liquidity. Cash, term deposits, or an offset account.
  • 3 to 7 years (medium term): a diversified mix of income and growth.
  • 7 years plus (long term): growth-focused assets with disciplined risk management.

Align each dollar with a job: emergency fund, debt choices, home or investment property plans, children’s education, retirement savings, or charitable giving.

Step 4: Tax and rules to consider

Australia has no inheritance or estate tax. You can still face tax on income or gains from inherited assets. Seek written advice before selling or restructuring. 

  • Property. Capital Gains Tax (CGT) can apply when you sell. A main-residence exemption may be available in some cases and there is a two-year timing rule, with possible extensions in limited circumstances. The ATO has more information on extensions to the 2-year ownership period.
  • Shares and managed funds. You usually inherit the deceased’s cost base. Future gains or income may be taxable in your hands.
  • Superannuation death benefits. Tax depends on your relationship to the deceased and the components of the benefit. ATO guidance explains who counts as a dependant and how tax is applied.
  • Pension and benefits. A large inheritance can affect Centrelink assessments under the income and assets tests. Check how your position may change.

Step 5: Build a financial strategy

This is where professional inheritance financial advice makes a clear difference. A tailored strategy can help you:

  • Preserve capital while generating reliable income.
  • Create an optimised tax position.
  • Invest based on your risk profile and timeframes.
  • Plan for retirement or intergenerational goals.

Common strategies include:

  • Diversified portfolios. Combine cash, fixed income, Australian and global shares, property, and alternatives.
  • Superannuation contributions. Use concessional and non-concessional contributions where appropriate, subject to caps and personal circumstances.
  • Debt reduction or offset use. Compare the after-tax, after-fee return from investing with the guaranteed saving from reducing non-deductible debt.
  • Property investment. Weigh cash flow, rates, maintenance, tenancy risk, and diversification.
  • Philanthropy. Structured giving can align with your values and tax planning.

Step 6: Make considered debt decisions

A lump sum tempts quick mortgage paydowns or new borrowing. Test options with advice.

  • Offset first. Parking cash in an offset account can cut interest while keeping flexibility.
  • Compare outcomes. Paying down non-deductible debt is often strong, but do not drain all liquidity.
  • Avoid new lifestyle debt. Large purchases can wait until your plan is set.

Step 7: Invest with discipline

Good portfolios are simple, diversified, and low friction.

  • Use broad market building blocks supported by high-quality research.
  • Keep fees and taxes in focus.
  • Rebalance periodically to maintain your risk level.
  • Document an investment policy statement you can stick to when markets move.

Step 8: Update your own estate plan

An inheritance is a prompt to review your legal documents.

  • Update your will and enduring powers if your situation has changed.
  • Review super nominations and life insurance beneficiaries.
  • Consider a testamentary trust if suitable for family protection or flexibility.

Learn more about Estate Planning with a Morgans adviser.

Step 9: Avoid common mistakes

Many Australians make avoidable errors with inherited wealth, such as:

  • Making large purchases without a plan
  • Ignoring tax consequences when selling assets
  • Failing to diversify or taking concentrated bets
  • Chasing high returns promised by unlicensed operators
  • Not seeking professional advice early enough

Use checklists, document your decisions, and keep a record of key statements and dates.

Step 10: Work with a Morgans financial adviser

Every inheritance is unique, and so is your financial journey. A Morgans adviser can help you:

  • Clarify goals, timelines, and trade-offs
  • Model debt vs invest decisions
  • Design a diversified portfolio to suit your risk profile
  • Coordinate with your accountant and solicitor on tax and estate matters
  • Set up a review rhythm so your plan stays on track

Contact us today for a free consultation with a Morgans adviser. Let us help you turn your inheritance into long-term financial security.

Learn more with our superannuation advice, financial planning, retirement and estate planning

      
Contact us
      

Frequently asked questions

1) Do I pay tax on inherited money in Australia?
There is no inheritance or estate tax. You may still pay tax on income or gains from inherited assets. CGT can apply if you sell property or shares you inherited. Tax may apply to some superannuation death-benefit payments depending on your relationship to the deceased and the components of the benefit.

2) Should I pay off my home loan or invest the inheritance?
It depends on interest rates, risk tolerance, cash flow, and timeframes. Many clients park funds in an offset account first, then decide with advice. Compare the saving from reducing non-deductible debt with the expected after-tax return from investing. A written plan helps you commit to the path you choose.

3) What if I inherit a house?
Decide whether to live in it, rent it, or sell. Each option has different tax, cost, and lifestyle impacts. Keep records of valuations, costs, and dates. Speak to your adviser and tax specialist before you sign a contract. ATO guidance covers CGT rules and timing, including the two-year rule and limited extension grounds.

4) Who should I talk to first?
Start with a licensed financial adviser and a tax accountant. If property or complex structures are involved, engage a solicitor. Your financial adviser can coordinate the team and build a step-by-step plan. 

Read more